MYR Pharma is focused on the development of Myrcludex B, a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections.
The drug targets the protein NTCP on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Myrcludex B has shown an excellent safety profile and antiviral efficacy in several clinical trials. The drug has received Orphan Designatio...
MYR Pharma is focused on the development of Myrcludex B, a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections.
The drug targets the protein NTCP on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Myrcludex B has shown an excellent safety profile and antiviral efficacy in several clinical trials. The drug has received Orphan Designations for the treatment of HDV infection from EMA and FDA. Myrcludex B has been added to a short list of drugs eligible for the PRIME (PRIority MEdicine) scheme by the European Medicines Agency
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.